Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 4
2016 2
2017 3
2018 6
2020 5
2021 5
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: kanoun s. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
FDG-PET/CT in Lymphoma: Where Do We Go Now?
Al Tabaa Y, Bailly C, Kanoun S. Al Tabaa Y, et al. Among authors: kanoun s. Cancers (Basel). 2021 Oct 18;13(20):5222. doi: 10.3390/cancers13205222. Cancers (Basel). 2021. PMID: 34680370 Free PMC article.
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Ghesquières H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac AC, Guidez S, Touati M, Laribi K, Morschhauser F, Bonnet C, Waultier-Rascalou A, Orsini-Piocelle F, André M, Fournier M, Morand F, Berriolo-Riedinger A, Burroni B, Damotte D, Traverse-Glehen A, Quittet P, Casasnovas O. Ghesquières H, et al. Among authors: kanoun s. Blood. 2024 Mar 14;143(11):983-995. doi: 10.1182/blood.2023021564. Blood. 2024. PMID: 37979133 Clinical Trial.
Prognostic Value of 18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
Carlier T, Frécon G, Mateus D, Rizkallah M, Kraeber-Bodéré F, Kanoun S, Blanc-Durand P, Itti E, Le Gouill S, Casasnovas RO, Bodet-Milin C, Bailly C. Carlier T, et al. Among authors: kanoun s. J Nucl Med. 2024 Jan 2;65(1):156-162. doi: 10.2967/jnumed.123.265872. J Nucl Med. 2024. PMID: 37945379
Interim PET in Hodgkin Lymphoma: Is It So Useless?
Meignan M, Cottereau AS, Deau B, Kanoun S, Berriolo-Riedinger A, Casasnovas O. Meignan M, et al. Among authors: kanoun s. J Nucl Med. 2017 Jul;58(7):1180. doi: 10.2967/jnumed.117.190462. Epub 2017 Mar 2. J Nucl Med. 2017. PMID: 28254870 Free article. No abstract available.
"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.
Lapierre L, Syrykh C, Largeaud L, Cabarrou B, Filleron T, Oberic L, Kanoun S, Coster L, Laurent C, Branco B, Gadaud N, Récher C, Brechemier D, Balardy L, Vergez F, Ysebaert L, Gauthier M. Lapierre L, et al. Among authors: kanoun s. Hematol Oncol. 2022 Oct;40(4):805-808. doi: 10.1002/hon.2985. Epub 2022 Mar 8. Hematol Oncol. 2022. PMID: 35246868 No abstract available.
34 results